DUBAI, United Arab Emirates, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ...
TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...
Hear from McLaren Mastercard Formula 1 driver Oscar Piastri and Team Principal Andrea Stella after Day 3 of running for the ...
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of ...
Formula 1’s first three-day pre-season test in Bahrain concluded with Mercedes and Kimi Antonelli at the top of the ...
A Relay Protection Tester is designed to simulate electrical quantities such as current, voltage, frequency, and phase, allowing engineers to test protective relays under controlled conditions.
Apple has moved on to the Release Candidate phase of the beta cycle for macOS Tahoe 26.3, iOS 26.3, and iPadOS 26.3. The new ...
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in ...
Investor's Business Daily on MSN
BridgeBio unveils positive results for its most 'hotly debated' phase 3 drug
BridgeBio unveiled promising results Thursday for its "hotly debated" final-phase asset: a potential treatment for ...
Cold functional tests have been completed at unit 3 of the Sanmen nuclear power plant in China's Zhejiang province, China ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results